AstraZeneca PLC
The market capitalisation of AstraZeneca has reached £200 billion for the first time, marking a significant milestone for the Cambridge-based pharmaceuticals group. The company's shares, led by CEO Sir Pascal Soriot, have been on a upward trajectory for years, driven by the launch of blockbuster medicines and ambitious
AstraZeneca PLC
The top 200 companies in the UK, ranked by market capitalization, have been released by Morningstar. The rankings provide a snapshot of the current market landscape, showcasing the largest and most valuable companies in the UK. Key Takeaways: * The top 10 companies in the UK by market capitalization are: Shell,
Molecular diagnostic techniques
The molecular diagnostics market is experiencing significant growth due to the increasing prevalence of infectious diseases and cancer, as well as a rising awareness and adoption of personalized medicine. The market is expected to grow from USD 15.60 billion in 2023 to USD 37.00 billion by 2031, at
Pharmaceutical industry
Pankaj Pandey, Head Research at ICICIdirect.com, shares his views on the current market trends, highlighting his bullish biases on select sectors such as pharma, autos, and realty majors. He also expresses his skepticism about the FMCG and IT sectors, citing structural challenges and uncertain growth prospects. Key Takeaways: * Pankaj
Pfizer Inc.
UK pharmaceutical company Glaxo's RSV vaccine has been overlooked by the NHS in favor of a cheaper alternative from Pfizer, highlighting a broader issue of the UK's commitment to preventative medicine and domestic pharmaceutical innovation. The decision comes despite the GSK vaccine being 10% more efficacious
Pharmaceutical industry
The specialty pharmaceuticals market is expected to grow significantly over the next five years, driven by the increasing demand for research and development (R&D) and government healthcare expenditure. The market size is expected to grow by USD 331.12 billion from 2022 to 2027, with a compound annual
Pharmaceutical industry
The endocrinology drugs market is expected to experience significant growth over the next five years, driven by the increasing prevalence of endocrine disorders such as diabetes. The market is segmented by distribution channel, therapy area, and geography, with North America contributing 45% to the growth of the global market. The
Cybernet Data Systems Inc.
Zai Lab Limited and its partner argenx have announced the approval of VYVGART (efgartigimod alfa injection) by China's National Medical Products Administration for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. This approval marks a significant milestone in the
Cybernet Data Systems Inc.
KPMG LLP, the independent registered public accounting firm for Canopy Growth Corporation, has declined to stand for reelection and resigned as the Company's independent registered public accounting firm, effective June 22, 2023. The Audit Committee of the board of directors of the Company accepted KPMG's resignation
Cybernet Data Systems Inc.
Pfizer Inc. has made significant progress in its planned acquisition of Seagen Inc. through a merger, with the parties having filed their respective notification and report forms pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The acquisition, first announced on March 12, 2023, is subject to the expiration or
Cybernet Data Systems Inc.
Pursuant to a previously disclosed Agreement and Plan of Merger, Seagen Inc. has entered into an agreement with Pfizer Inc. to merge the companies, with Seagen surviving as a wholly-owned subsidiary of Pfizer. The merger is subject to regulatory approvals and clearances in the United States and certain other jurisdictions.
Information technology services industry
Canopy Growth Corporation, in a current report filed with the Securities and Exchange Commission on May 10, 2023, disclosed that its BioSteel Sports Nutrition Inc. business unit had incorrectly accounted for sales, prompting an internal review and planned restatement of prior financial statements. The company initiated an internal review of
